S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
OTCMKTS:PBIO

Pressure BioSciences - PBIO Stock Forecast, Price & News

$1.39
0.00 (0.00%)
(As of 03/24/2023 08:52 PM ET)
Add
Compare
Today's Range
$1.38
▼
$1.42
50-Day Range
$1.25
▼
$2.14
52-Week Range
$0.91
▼
$2.40
Volume
8,500 shs
Average Volume
23,284 shs
Market Capitalization
$21.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

PBIO stock logo

About Pressure BioSciences (OTCMKTS:PBIO) Stock

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts. As of August 2, 2022, Pressure BioSciences, Inc. operates as a subsidiary of Emergent Health Corp.

Receive PBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pressure BioSciences and its competitors with MarketBeat's FREE daily newsletter.

PBIO Stock News Headlines

March 24, 2023 | americanbankingnews.com
SeqLL (NASDAQ:SQL) & Pressure BioSciences (OTCMKTS:PBIO) Head to Head Survey
March 22, 2023 | finanznachrichten.de
Pressure BioSciences Inc.: Pressure BioSciences Receives $1.5M Contract for UltraShear Nanoemulsified CBD
March 27, 2023 | Tradewins (Ad)
Modern Day Options Trading For Beginners!
These days it takes more than willpower to succeed on Wall Street and for new traders, even small mistakes can sink an account! With "Your Guide To Successful Options Trading" by expert Wendy Kirkland, you can avoid new trader pitfalls and learn to earn in this vicious market. pixel
March 22, 2023 | seekingalpha.com
Pressure BioSciences lands $1.5M order for its UltraShear Nanoemulsified CBD
March 22, 2023 | finance.yahoo.com
Pressure BioSciences Receives $1.5M Contract for UltraShear Nanoemulsified CBD
March 1, 2023 | finance.yahoo.com
Pressure BioSciences Announces the Exchange of Over $10 Million of Debt into Equity
February 26, 2023 | benzinga.com
InvestorNewsBreaks – Pressure BioSciences Inc.'s (PBIO) UltraShear(TM) Platform Holds Significant Potential in the Edible Cannabis Sector
February 25, 2023 | benzinga.com
Pressure BioSciences' Breakthrough UltraShear Nanoemulsion Processing Could Help Revolutionize The Edible Cannabis Industry
March 27, 2023 | Stansberry Research (Ad)
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
February 2, 2023 | msn.com
Pressure BioSciences bags largest single order for 16 PCT instruments
January 19, 2023 | finanznachrichten.de
Pressure BioSciences Inc.: Pressure BioSciences Nanoemulsions Platform Forging Game-Changing Future for Cannabis Industry
January 19, 2023 | finance.yahoo.com
Pressure BioSciences Nanoemulsions Platform Forging Game-Changing Future for Cannabis Industry
December 22, 2022 | finance.yahoo.com
Pressure BioSciences Gives Guidance for Strong Q4 2022 Sales Followed by Rapid Revenue Growth from Multiple Large Industries in 2023
December 13, 2022 | finance.yahoo.com
Pressure BioSciences Announces First Commercial Production of Revolutionary UltraShear Nanoemulsion Product Shipped, Booked, and Paid
December 7, 2022 | finance.yahoo.com
Pressure BioSciences Partnership with QVC Skincare Leader Dr. Denese SkinScience Yields Unprecedented Effectiveness in Skin Tightening and Wrinkle Reduction
December 5, 2022 | finance.yahoo.com
Pressure BioSciences Securing and Fulfilling UltraShear Nanoemulsions Contracts, Discussed on "Stock Day Podcast"
November 22, 2022 | finance.yahoo.com
Pressure BioSciences, Inc. Reports Q3 2022 Financial Results and Offers Business Update on Ultra Shear Technology Nanoemulsions Commercialization Progress
October 26, 2022 | finance.yahoo.com
Pressure BioSciences and Leading Cosmeceuticals Innovator Dr. Denese SkinScience to Introduce Revolutionary UST Nanoemulsion Hair Regrowth Product in 2023
October 22, 2022 | forbes.com
Normal Blood Pressure Numbers According to Age
October 21, 2022 | finance.yahoo.com
Pressure BioSciences, Inc. (PBIO)
October 11, 2022 | finance.yahoo.com
Pressure BioSciences and Leading Cosmeceuticals Company Dr. Denese SkinScience Present Their Partnership Progress in FORCE Family Office October 13th Webinar
September 28, 2022 | finance.yahoo.com
Imminent Commercial Launch of Revolutionary UST Processing Method to be Focus of Pressure BioSciences Presentation at Emerging Growth Conference 40 on September 28, 2022
September 27, 2022 | finance.yahoo.com
Unique Advantages and Commercial Process Scalability of Pressure BioSciences Revolutionary UST Platform Illuminated at the Conference of Food Engineering 2022
September 13, 2022 | finance.yahoo.com
Pressure BioSciences to Expand on Pivotal Change in Business Strategy with Presentation at H. C. Wainwright Annual Global Investment Conference on September 13th
August 25, 2022 | msn.com
Novartis To Spinoff Sandoz Business To Create #1 European Generics Company
August 24, 2022 | finance.yahoo.com
Pressure BioSciences Secures Pivotal Cosmeceuticals Partnership for UST Platform With Dr. Denese SkinScience, 20-Year Leader With Over $0.5 Billion in QVC Sales
August 20, 2022 | marketwatch.com
InvestorNewsBreaks - Pressure BioSciences Inc. (PBIO) Enters Strategic Agreement with Canopy CBD Farms
See More Headlines
Receive PBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pressure BioSciences and its competitors with MarketBeat's FREE daily newsletter.

PBIO Company Calendar

Last Earnings
11/17/2020
Today
3/27/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:PBIO
CUSIP
N/A
CIK
830656
Web
www.pressurebiosciences.com
Phone
508-230-1828
Fax
508-230-1829
Employees
12
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.64)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-20,150,000.00
Net Margins
-1,078.50%
Pretax Margin
-1,078.43%
Return on Equity
N/A
Return on Assets
-541.46%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.06
Quick Ratio
0.02

Sales & Book Value

Annual Sales
$2 million
Price / Sales
10.72
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($2.63) per share
Price / Book
-0.53

Miscellaneous

Outstanding Shares
15,420,000
Free Float
13,804,000
Market Cap
$21.43 million
Optionable
Not Optionable
Beta
0.77

Key Executives

  • Mr. Richard T. Schumacher (Age 73)
    Founder, Pres, CEO, Treasurer, Interim CFO, Clerk & Director
    Comp: $355.18k
  • Dr. Alexander V. Lazarev Ph.D. (Age 58)
    Chief Science Officer
    Comp: $202.34k
  • Dr. Edmund Y. Ting Ph.D. (Age 68)
    Sc.D. Ph.D., Sr. VP of Engineering
    Comp: $256.92k
  • John B. Hollister
    Director of Sales & Marketing

Key Competitors

View All Competitors













PBIO Stock - Frequently Asked Questions

How have PBIO shares performed in 2023?

Pressure BioSciences' stock was trading at $1.30 at the beginning of the year. Since then, PBIO stock has increased by 6.9% and is now trading at $1.39.
View the best growth stocks for 2023 here.

Are investors shorting Pressure BioSciences?

Pressure BioSciences saw a decline in short interest in March. As of March 15th, there was short interest totaling 1,700 shares, a decline of 71.2% from the February 28th total of 5,900 shares. Based on an average daily volume of 47,100 shares, the short-interest ratio is currently 0.0 days.
View Pressure BioSciences' Short Interest.

How were Pressure BioSciences' earnings last quarter?

Pressure BioSciences, Inc. (OTCMKTS:PBIO) released its earnings results on Tuesday, November, 17th. The company reported ($1.02) EPS for the quarter, beating analysts' consensus estimates of ($2.20) by $1.18. The business earned $0.53 million during the quarter.
Read the conference call transcript.

What other stocks do shareholders of Pressure BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pressure BioSciences investors own include Advanced Micro Devices (AMD), Allena Pharmaceuticals (ALNA), Ampio Pharmaceuticals (AMPE), Actinium Pharmaceuticals (ATNM), Anavex Life Sciences (AVXL), Aware (AWRE), Curaleaf (CURLF) and Walt Disney (DIS).

What is Pressure BioSciences' stock symbol?

Pressure BioSciences trades on the OTCMKTS under the ticker symbol "PBIO."

How do I buy shares of Pressure BioSciences?

Shares of PBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pressure BioSciences' stock price today?

One share of PBIO stock can currently be purchased for approximately $1.39.

How much money does Pressure BioSciences make?

Pressure BioSciences (OTCMKTS:PBIO) has a market capitalization of $21.43 million and generates $2 million in revenue each year. The company earns $-20,150,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis.

How can I contact Pressure BioSciences?

Pressure BioSciences' mailing address is 14 NORFOLK AVENUE, SOUTH EASTON MA, 02375. The official website for the company is www.pressurebiosciences.com. The company can be reached via phone at 508-230-1828, via email at ir@pressurebiosciences.com, or via fax at 508-230-1829.

This page (OTCMKTS:PBIO) was last updated on 3/27/2023 by MarketBeat.com Staff